OBI-888

OBI-888, a humanized monoclonal IgG1 antibody targeting Globo H, was evaluated in a Phase I–II study for advanced solid tumors. The study found OBI-888 to be safe and well-tolerated, with no maximum tolerated dose (MTD) reached and low incidence of adverse effects. Disease stabilization was observed in 28.6% and 20% of patients in Parts A and B, respectively, suggesting a cytostatic effect. Antibody-dependent cell-mediated cytotoxicity (ADCC) was induced after each OBI-888 dose, indicating ADCC as a potential mechanism of action. However, overall complement-dependent cytotoxicity (CDC) activity was low. Given the limited antitumor activity despite prolonged disease stabilization in some patients, further development of OBI-888 is not planned.